Filipov Hülya, Kavla Yasin, Şahin Serdar, Gökler Mehmet Enes, Turan Şenol
Department of Psychology, Dogus University, Istanbul, Turkey.
Department of Psychiatry, Cerrahpaşa School of Medicine, Istanbul University-Cerrahpaşa, Fatih, Turkey.
Transgend Health. 2023 Mar 31;8(2):168-174. doi: 10.1089/trgh.2021.0139. eCollection 2023 Apr.
Gender-affirming hormone therapy (GAHT) is one of the most important therapeutic interventions sought by people with gender dysphoria (GD). In the present study, we aimed to examine the effects of GAHT on body satisfaction, self-esteem, quality of life, and psychopathology in people with female-to-male (FtM) GD.
Thirty-seven FtM GD participants who did not receive any gender-affirming therapy, 35 FtM GD participants who received GAHT for over 6 months, and 38 cisgender women were included in the study. The Body Cathexis Scale (BCS), Rosenberg Self Esteem Scale (RSES), World Health Organization's Quality of Life Questionnaire Brief Form (WHOQOL-BREF), and Symptom Checklist-90-Revised (SCL-90-R) were completed by all participants.
The BCS scores of the untreated group were significantly lower than both the GAHT group and the female controls (<0.001); while the WHOQOL-BREF-psychological health scores of the untreated group were significantly lower than those of the female controls (=0.003). The psychoticism subscale scores on the SCL-90-R of the untreated group were higher than those of the GAHT group (=0.04) as well as the female controls (=0.003). With regard to the RSES, there were no significant differences between the groups.
Our findings suggest that people with FtM GD who receive GAHT are more satisfied with their bodies and have less psychopathological problems compared to those who do not receive GAHT, but their quality of life and self-esteem do not change as a result of GAHT.
性别肯定激素疗法(GAHT)是性别焦虑症(GD)患者寻求的最重要的治疗干预措施之一。在本研究中,我们旨在研究GAHT对女性变男性(FtM)性别焦虑症患者的身体满意度、自尊、生活质量和精神病理学的影响。
本研究纳入了37名未接受任何性别肯定治疗的FtM性别焦虑症参与者、35名接受GAHT超过6个月的FtM性别焦虑症参与者以及38名顺性别女性。所有参与者均完成了身体投入量表(BCS)、罗森伯格自尊量表(RSES)、世界卫生组织生活质量问卷简表(WHOQOL-BREF)和症状自评量表90修订版(SCL-90-R)。
未治疗组的BCS得分显著低于GAHT组和女性对照组(<0.001);而未治疗组的WHOQOL-BREF心理健康得分显著低于女性对照组(=0.003)。未治疗组SCL-90-R的精神病性分量表得分高于GAHT组(=0.04)以及女性对照组(=0.003)。关于RSES,各组之间没有显著差异。
我们的研究结果表明,与未接受GAHT的FtM性别焦虑症患者相比,接受GAHT的患者对自己的身体更满意,精神病理学问题更少,但GAHT并未改变他们的生活质量和自尊。